|View printer-friendly version|
Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update
“Our team at
“We extended our cash runway into 2022 with the completion of our previously announced convertible debt facility,” said
Recent Highlights and Business Developments
2019 Third Quarter Financial Results
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of the company’s trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Source: Spring Bank Pharmaceuticals, Inc.